Articles related to VASOMOTOR SYMPTOMS

Conference presenters highlighted gaps in menopause medication coverage and follow-up support, describing opportunities for pharmacist involvement while offering no comparative evidence that employer-sponsored programs improve symptoms, adherence, or workplace outcomes.

A menopause-associated blood protein pattern was linked to poorer cognition and Alzheimer’s disease in older women across observational cohorts. Replication supports research interest, but the findings do not establish causality, individual prediction, or hormone-therapy prevention benefits.

Healthline reports that updated ACOG guidance strongly supports hormone therapy for vasomotor symptoms and related sleep disturbance in eligible patients. Nonhormonal options also receive strong recommendations; evidence remains insufficient for hormone therapy targeting depressive symptoms.

ACP places estrogen-based therapy first in its pharmacologic pathway for menopausal vasomotor symptoms, with nonhormonal alternatives for contraindications or intolerance. Recommendation strength and evidence certainty vary, and long-term safety evidence remains limited.

Hormone therapy status was associated with differences in diet, physical activity, and sleep guideline adherence in a cross-sectional analysis of more than 10,000 women.

More than half of women aged 50–80 reported sleep problems in a cross-sectional survey analysis, with symptomatic menopausal women significantly more likely to be affected than those without menopausal symptoms.